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ABSTRACT
Background
Age-related macular degeneration (AMD) is the most common cause of irreversible visual
impairment in the developed world. The two forms of advanced AMD, geographic atrophy and
neovascular AMD, represent different pathological processes in the macula that lead to loss of
central vision. Soft drusen, characterized by deposits in the macula without visual loss, are
considered to be a precursor of advanced AMD. Recently, it has been proposed that a common
missense variant, Y402H, in the Complement Factor H (CFH) gene increases the risk for
advanced AMD. However, its impact on soft drusen, GA, or neovascular AMD—or the
relationship between them—is unclear.
Methods and Findings
We genotyped 581 Icelandic patients with advanced AMD (278 neovascular AMD, 203 GA,
and 100 with mixed neovascular AMD/GA), and 435 with early AMD (of whom 220 had soft
drusen). A second cohort of 431 US patients from Utah, 322 with advanced AMD (244
neovascular AMD and 78 GA) and 109 early-AMD cases with soft drusen, were analyzed. We
confirmed that the CFH Y402H variant shows significant association to advanced AMD, with
odds ratio of 2.39 in Icelandic patients (p ¼ 5.9 3 10
 12) and odds ratio of 2.14 in US patients
from Utah (p¼2.0310
 9) with advanced AMD. Furthermore, we show that the Y402H variant
confers similar risk of soft drusen and both forms of advanced AMD (GA or neovascular AMD).
Conclusion
Soft drusen occur prior to progression to advanced AMD and represent a histological feature
shared by neovascular AMD and GA. Our results suggest that CFH is a major risk factor of soft
drusen, and additional genetic factors and/or environmental factors may be required for
progression to advanced AMD.
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Age-related macular degeneration (AMD) includes a wide
range of phenotypes. Early AMD is characterized mainly by
the presence of soft drusen in the macula without visual loss,
while advanced AMD is characterized by geographic atrophy
(GA or dry AMD) and neovascular AMD (wet AMD) with
visual loss. Despite the rising prevalence of AMD as a result of
increasing life expectancy, its underlying pathogenesis is
poorly understood and there are limited treatment options
available. Nutritional supplements and antagonists of vascu-
lar endothelial growth factor have been reported to decrease
visual loss in neovascular AMD somewhat [1]. Drusen are
comprised of small yellowish, extracellular deposits of lipid,
protein, and cellular debris, formed beneath the retinal
pigment epithelium (RPE), a tissue that underlies the photo-
receptor cells. Biochemical analysis of drusen have indeed
resulted in identiﬁcation of complement components and
inﬂammatory modulators [2–8]. Soft drusen and pigmentary
abnormalities of the RPE are considered to be an early
indication of risk of developing advanced AMD. GA is a
consequence of the degeneration of the photoreceptor cells
and the RPE. Neovascular AMD is characterized by abnormal
growth of capillaries from the choroid and by subsequent
exudation of ﬂuid, lipid, and blood.
Several genome-wide linkage scans for AMD including ours
(unpublished data) have found suggestive linkage on chro-
mosome 1q [9–15]. The addition of markers within the
linkage peak led to recent reports by ﬁve groups that there is
an association between a common missense variant (Y402H)
in CFH and AMD in the United States [3,16–19]. The Y402H
allele was present in at least 60% of AMD patients with risk
ratios of between 2.0 and 3.5 for one risk allele, and with risk
ratios of between 3.3 and 7.4 for carriers of two risk alleles. It
has been postulated that the Y402H variant may lead to
decreased binding to CRP and heparin and therefore less
inhibition of the complement pathway, causing overactivity
and deposition of the complement pathway proteins [20].
CFH protein has been detected in choriocapillaris and within
soft drusen [3].
However, the question of how the Y402H allele contributes
to the different subtypes of AMD has not been properly
addressed, owing either to insufﬁcient clinical information or
to sample size, as neovascular AMD dominates the patient
cohorts in most previously reported studies [3,16–19].
In order to investigate the association between CFH and
AMD we performed genotype–phenotype correlations on
different clinical subtypes of early and advanced AMD in US
and European populations.
Methods
Patients
This study was approved by the Data Protection Authority
of Iceland and the National Bioethics Committee of Iceland,
and the Institutional Review Board of the University of Utah.
All participants signed written informed consent prior to
participation in the study. All personal identiﬁers associated
with blood samples, medical information, and genealogy were
encrypted. For samples from Iceland, encryption was carried
out by the Data Protection Authority, using a third-party
encryption system [21]. The Icelandic cohort recruited by
DeCODE Genetics has detailed phenotypic information for
2,220 individuals, ie 1,112 patients with neovascular AMD, GA,
or early AMD, and 1,108 of their unaffected relatives.
Probands were recruited from a list of 2,840 consecutive
patients diagnosed with AMD or early AMD at the University
Eye Clinic, Reykjavik, or listed in the Icelandic Registry for the
Blind during the years 1980–2001, together with relatives.
Population controls were not related to the AMD cohort and
did not include any ﬁrst- or second-degree relative pair. A
second control group (longevous controls) included 171
unrelated individuals, aged 90 y or older, who had no signs
of advanced AMD, diagnosed based on their ability to see ﬁne
detail, including print, as assessed in Section D1 of the
Minimum Data Set of the Resident Assessment Instrument
[22]. Since the prevalence of AMD increases dramatically with
age, this group represents healthy ‘‘supercontrols’’ for AMD.
A second sample of AMD patients were recruited in Utah at
the Moran Eye Center of the University of Utah, and were age-
matched with controls with normal eye examinations (indi-
viduals aged 60 y or older, with no drusen or RPE changes).
All participants in both populations went through a
standard examination protocol and visual-acuity measure-
ments. Slitlamp biomicroscopy of the fundi using 90-diopter
lenses was performed. A pair of stereoscopic color fundus
photographs (508) were taken, centered on the fovea using a
Topcon fundus camera (Topcon TRV-50VT, Topcon Optical
Company, Tokyo, Japan) by a trained ophthalmic photogra-
pher. Grading was carried out using a standard grid
classiﬁcation suggested by the International Age-Related
Maculopathy Epidemiological Study Group for age-related
maculopathy and AMD [23]. All abnormalities in the macula
were recorded, including type, size, and number of drusen as
well as the presence of hyperpigmentation and hypopigmen-
tation, together with advanced AMD.
Genotyping
The Icelandic cohort that was genotyped included 581
patients with advanced AMD and 435 patients with early
AMD, and allele frequencies were compared to that of either
891 population controls or 171 longevous healthy controls
(Table 1). The Utah cohort of 244 patients with neovascular
AMD, 78 patients with GA, and 109 patients with early AMD
with soft drusen was genotyped, and allele frequencies were
compared to 203 age-matched healthy controls. A TaqMan
assay (Applied Biosystems, Foster City, California, United
States) was performed on a 384-well GeneAmp PCR System
9700 (Applied Biosystems) used for PCR to genotype the
Icelandic cohort. A direct DNA- sequencing method was used
on an ABI 3100 genetic analyzer (Applied Biosystems) to
genotype the Utah cohort.
Data Analysis
For the single-marker association of the CFH Y402H
variant (rs1061170), we used Fisher’s exact test to calculate
one-sided p-values for the at-risk allele. As the patient cohort
was recruited as families for a linkage analysis, we also
repeated the test for association, correcting for the related-
ness of the patients by extending a variance-adjustment
procedure described previously [24] for sib-ships to apply to
general familial relationships. Using the variance-adjustment
procedure, the variance of the test statistic is adjusted to take
into account the decrease in the effective sample size
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independent. Both unadjusted and adjusted p-values are
presented for comparison. We calculate the odds ratio (OR)
of the frequency of the at-risk allele as OR ¼ p/(1 p)/s/(1 s),
where p and s are the frequency of the at-risk allele in the
patients and in the controls, respectively. In the case of
population controls and assuming the multiplicative model,
in which the risks of the two alleles of the single-nucleotide
polymorphism a person carries multiply [25,26], this corre-
sponds to an estimate of the relative risk of the mutation
compared to the wild-type. Speciﬁcally, with population
controls and the multiplicative model, it can be shown
through Bayes’ Rule that the OR, as deﬁned above,
corresponds to Risk(CT)/Risk(TT) ¼ Risk(CC)/Risk(CT), where
C is the mutated allele and T the wild-type, and Risk is the
probability of disease given the genotype.
On the basis of the frequency of the at-risk allele and the
relative risk, we calculate the population-attributable risk or
the reduction in the number of disease cases if the at-risk
allele was removed from the population, again assuming the
multiplicative model. Conﬁdence intervals of relative risks
and ORs were based on the variance-adjusted tests for
association, assuming a log-normal distribution. To avoid
confusion and to be consistent, we report the results as OR
when using healthy controls and as relative risk when using
population controls.
Results
In agreement with previous reports [3–19], the Y402H
allele confers an OR of 2.32 when comparing Icelandic
patients with neovascular AMD to healthy controls. Based on
the comparison with population controls, the relative risk of
the mutation is estimated to be 1.99 with a corresponding
estimated population-attributable risk of 0.48. The Y402H
variant also contributes to GA, with OR of 2.27. The patient
group with mixed GA/neovascular AMD gave similar results
with OR of 2.92. Thus, the Y402H allele contributes equally to
GA and neovascular AMD in Icelandic patients with advanced
AMD (Table 1).
The comparable association to neovascular AMD and GA
was replicated in the Utah cohort, giving ORs of 2.17 and
2.05, respectively (Table 2). Therefore, we conclude that the
CFH variant contributes equally to GA and neovascular AMD
in our European and US cohorts.
Furthermore, the Y402H variant contributes to soft drusen
in early AMD, with similar ORs in the Icelandic and Utah
study groups of 2.52 and 2.10, respectively (see Tables 1 and
2). In contrast, the variant does not show signiﬁcant
association to pigmentary changes found in early AMD. In
Iceland we observed signiﬁcant association (p ¼ 0.01) to hard
drusen but with a lower OR (1.57) (Table 1). A signiﬁcant
difference in CFH Y402H allele frequencies was observed
when patients with soft drusen were compared with an
unrelated set of patients with hard drusen (p ¼ 0.011). This
CFH variant also confers increased risk although this is not
signiﬁcant when comparing hard drusen to controls in the
Utah cohort (see Table 2).
We also typed the CFH Y402H allele in four ethnically
diverse populations from the International HapMap project
[27]; Caucasians, residents of Utah with ancestry from
northern and western Europe (59), Yorubians, residents of
Nigeria (57), Japanese (31), and Chinese (44). The allele
frequencies for CFH Y402H in Caucasians and Africans were
Table 1. Association between Subphenotypes of AMD and CFH Y402H Variant in the Icelandic Cohort
Phenotype Subphenotype n Population Controls Healthy Controls
Frq p-Value p-Value
a RR PAR p-Value p-Value
a OR
AMD Advanced AMD 581 0.567 2.1 3 10
 21 1.2 3 10
 19 2.05 (1.75–2.40) 0.50 2.5 3 10
 12 5.9 3 10
 12 2.39 (1.86–3.07)
Neovascular only 278 0.559 1.4 3 10
 12 4.7 3 10
 12 1.99 (1.63–2.43) 0.48 1.3 3 10
 9 2.1 3 10
 9 2.32 (1.75–3.07)
Mixed neovascular/GA 100 0.615 8.9 3 10
 10 1.2 3 10
 9 2.50 (1.85–3.38) 0.60 2.9 3 10
 9 3.6 3 10
 9 2.92 (2.03–4.20)
GA only 203 0.554 1.1 3 10
 9 7.7 3 10
 9 1.95 (1.55–2.46) 0.47 2.9 3 10
 8 7.4 3 10
 8 2.27 (1.67–3.08)
Early-AMD changes Soft drusen 220 0.580 5.0 3 10
 13 9.0 3 10
 12 2.16 (1.73–2.70) 0.53 2.4 3 10
 10 8.5 3 10
 10 2.52 (1.87–3.40)
Hard drusen only 93 0.462 0.032 0.035 1.35 (0.98–1.87) 0.22 0.0096 0.0104 1.57 (1.07–2.30)
Pigments only 122 0.398 0.430 0.43 1.03 (0.74–1.43) 0.03 0.16 0.16 1.21 (0.83–1.76)
Controls Population controls 891 0.389
Healthy controls 171 0.354
Shown are calculations for the C allele of the CFH Y402H variant and the corresponding number of affected individuals (n), the allelic frequency in affected individuals (Frq), one-sided Fisher’s exact p-value, relative risk (RR), OR, and population-
attributable risk (PAR). The hard-drusen cohort consisted of individuals solely with hard drusen, with no sign of soft drusen or pigmentary changes. Individuals were included in the pigmentary changes (Pigments only) cohort if they showed
no sign of hard drusen or soft drusen. The healthy (longevous) controls had normal visual acuity.
ap-Values adjusted for the relatedness of patients.
DOI: 10.1371/journal.pmed.0030005.t001
Table 2. Association between Subphenotypes of AMD and CFH
Y402H Variant in the Utah Cohort
Phenotype Subphenotype n Age-Matched Healthy Controls
Frq p-Value OR
AMD Advanced AMD 322 0.587 2.0 3 10
 9 2.14 (1.66–2.75)
Neovascular only 244 0.590 8.5 3 10
 9 2.17 (1.66–2.84)
GA only 78 0.577 0.00011 2.05 (1.40–3.00)
Early-AMD
changes
Soft drusen 109 0.583 8.4 3 10
 6 2.10 (1.50–2.95)
Hard drusen only 0 65 0.477 0.072 1.37 (0.91–2.06)
Controls Age-matched
healthy controls
203 0.399
Shown are calculations for the C allele of the CFH Y402H variant and the corresponding number of unrelated
affected individuals (n), the allelic frequency in affected individuals (Frq), p-value, and OR. The control group was
age-matched to the patient group and the individuals had normal eye examinations.
DOI: 10.1371/journal.pmed.0030005.t002
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Asians—8.1% in the Japanese and 6.8% in the Chinese.
Discussion
We have shown that the CFH Y402H allele confers
signiﬁcant risk to neovascular AMD, GA, and soft drusen in
early AMD in US and European Caucasian populations. The
effect of the CFH Y402H allele on soft drusen in early AMD is
similar to its effect on the advanced forms of AMD,
neovascular AMD, and GA. Advanced AMD is considered to
be one disease with two different end-stage lesions, i.e.,
choroidal neovasculariztion and GA. Leaky choroidal neo-
vascular blood vessels between Bruch’s membrane and RPE
are seen typically in neovascular AMD, while GA is
characterized by RPE atrophy and overlying photoreceptor
loss. Soft drusen located between the RPE and Bruch’s
membrane are usually precursors of both forms of advanced
AMD. The 5-y incidence of soft drusen in the Reykjavik Eye
Study, a population-based epidemiological study of individ-
uals aged 50 y and older [28,29], was found to be similar to
that of the Beaver Dam Eye Study in the US [30], and the Blue
Mountains Eye Study in Australia [31]. Neovascular AMD
outnumbers GA by approximately three to one in both the
Beaver Dam Eye Study and the Blue Mountains Eye Study.
Similar ﬁgures were seen in most other Caucasian popula-
tions. In the Icelandic population under consideration here,
however, GA was found to outnumber neovascular AMD by
three to one, as reported in the Reykjavik Eye Study [28,29]. It
is an open question whether the high GA/neovascular AMD
ratio in Iceland is due to genetic or environmental factors
that increase the risk of GA or decrease the risk of
neovascular AMD. Consumption of fresh ﬁsh and ﬁshliver
oil with omega-3 polyunsaturated fatty acids among Ice-
landers is among the highest in the world [28]. Interestingly,
Seddon et al. [32] reported a trend for decreasing odds of
neovascular AMD with increasing amounts of omega-3 and
fresh-ﬁsh intake.
The discovery of CFH as an important AMD gene,
contributing to the common form of AMD and its con-
ﬁrmation by several groups, is a major advance towards
understanding the genetic risk and pathogenesis of AMD. It is
apparent that this single common variant confers similar risk
in all of the US populations tested and, furthermore, our
result for the association of the CFH variant to advanced
AMD in a European population is comparable to that in the
US. However, the previously reported studies had not
adequately addressed the effect of the CFH variant on GA
or early AMD. We therefore tested the reported variant in the
CFH region for association to the subtypes of AMD in both of
our cohorts.
Functionally, CFH is thought to aid in keeping the
complement pathway of the innate immune system in check.
It is tempting to postulate that a hypothetical lower activity of
complement H protein with the histidine variant may lead to
increased inﬂammation that would contribute to the neo-
vascular form of AMD as suggested before [17]. Alternatively,
others have suggested that it may have a direct role in soft-
drusen formation, which may also be linked to inﬂammation
[3]. Our results, showing that the CFH variant contributes
equally to GA and to neovascular AMD, would tend to refute
the ﬁrst hypothesis and lend support to the second.
Given that the protein component of soft drusen includes
members of the complement system (including Complement
H), we tested the effect of the CFH variant on risk of soft
drusen without advanced AMD. Interestingly, this CFH
variant confers risk of soft drusen with similar OR (2.52) as
with both forms of advanced AMD, even before the
fundoscopic ﬁndings and visual loss fulﬁl the criteria for
advanced AMD in two independent cohorts. Conversely,
there is little or no impact of the CFH variant on other
features such as pigmentary changes and hard drusen.
Therefore, it appears that the Y402H variant in CFH
contributes to the increased risk of advanced AMD largely
or entirely through its impact on the development of soft
drusen as a precursor of advanced AMD.
This observation may not be surprising given that soft
drusen is comprised, in part, of complement proteins
including CFH and its binding partner, complement 3b [20].
However, many more elderly patients develop soft drusen
than those who ultimately progress to advanced AMD.
Numerous epidemiological studies have shown that the
prevalence of soft drusen is two to three times greater than
that of advanced AMD [33]. The prevalence of soft drusen in
Caucasian populations increases with age at the same rate as
AMD. Most patients with soft drusen are without any visual
symptoms for decades, and only a fraction of individuals who
have soft drusen will eventually progress to AMD with visual-
acuity loss. For example in the Beaver Dam eye study, only
14% of the patients with soft drusen developed AMD over a
10-y period [30]. Interestingly, in persons of African origin
living in United States and Barbados, prevalence of early
AMD and soft drusen is slightly lower than in whites, but
advanced AMD is rare [34,35]. The allele frequency of the
Y402H is less (0.31 versus 0.39) in African Americans than in
Caucasians. Therefore, the prevalence discrepancy between
the early and advanced AMD in African Americans is
consistent with our hypothesis that CFH Y402H causes soft-
drusen formation, but it is not sufﬁcient for progression to
advanced AMD. To substantiate this hypothesis further, it will
be interesting to correlate the prevalence of soft drusen with
advanced AMD in Asian populations. Our analysis of the CFH
Y402H variant demonstrated that its frequency is less in
Asian populations: 0.08 in the Japanese samples and 0.07 in
the Chinese. Indeed, AMD in Asians is considered to be
infrequent, but careful genotype–phenotype correlation
studies are needed in non-Caucasian populations.
Signiﬁcant genetic inﬂuence in early AMD has been
demonstrated in a classical twin study comparing concord-
ance of 226 monozygotic and 280 dizygotic twin pairs, with
soft drusen and multiple hard drusen showing strong genetic
inﬂuences with heritability of 57% and 81%, respectively [36].
This is comparable to the heritability of advanced AMD [37].
However, we show that the CFH variant is a risk factor for soft
drusen, but not for hard drusen or pigmentary changes, per
se. Therefore, there may be other genes that inﬂuence the
appearance of hard drusen and pigmentary changes. In
addition, the difﬁculty in explaining the difference in the
ratio of the prevalences in neovascular AMD and GA across
populations through the CFH variant alone supports the
notion that additional genetic or environmental factors
contribute to the pathogenesis. It is likely that there are
other important genes, yet to be found, that contribute to the
PLoS Medicine | www.plosmedicine.org January 2006 | Volume 3 | Issue 1 | e5 0112
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have soft drusen.
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AMD, ARMD1, is 603075; and for the CFH gene is 134370.
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Background. The commonest cause of poor eyesight in later life in the
developed world is known as age-related macular degeneration (AMD).
The macula is the central part of the retina (the film-like membrane at
the back of the eye) which is the most sensitive and important for sharp
central vision. An early sign of AMD is what are called ‘‘drusen’’—
deposits of protein, fat, and cells—which doctors can see in the back of
the eye. There are two types of advanced AMD: so-called ‘‘wet’’ or
neovascular AMD (neovascular means ‘‘new vessel’’) and ‘‘dry’’ or
geographic atrophy AMD (atrophy means to waste away). Wet AMD
occurs when abnormal, fragile blood vessels grow under the macula
behind the retina. These blood vessels often leak blood and fluid, which
lift the macula. Dry AMD occurs as the light-sensitive cells in the macula
(the rods and cones) break down.
Why Was This Study Done? Although this disease is common, little is
understood about why it occurs, and current treatments have limited
efficacy. Previous studies have suggested that a gene in a particular part
of Chromosome 1 is linked to the chance of getting AMD. The
responsible gene is Complement Factor H (CFH), which codes for a
protein that is involved in keeping one part of the immune system in
check. A variant of CFH has been previously shown to be present more
frequently in people with advanced AMD compared to normal controls.
These investigators wanted to go further, to find out whether this variant
was more linked to the wet or to the dry type of AMD and to early AMD.
What Did the Researchers Do and Find? They looked at the variant of
CFH in two groups of patients with various types of AMD, 1,118 from
Iceland and 431 from Utah, and compared the results with people
without AMD from the same ethnic groups and age. As had been shown
before, they found that one variant of this gene occurred more
frequently in the wet form of AMD. However, they report two new
observations. First, the variant of CFH also confers risk for the dry form of
AMD and second, the variant confers similar risk to drusen in the early
form of AMD.
What Do These Findings Mean? It appears that this gene variant is
important early on in the development of AMD—which makes sense as
the protein for which this gene codes is involved in keeping the immune
system under control. The particular variant found here may not be as
efficient as the normal one—that is, it makes it more likely that
inflammation will develop in the eye. These findings do not have any
immediate implications for treatment, but they suggest that there are
other genes that cause the severe forms of AMD with blindness.
Where Can I Get More Information Online? Here are several Web sites
with information on macular degeneration.
MedlinePlus:
http://www.nlm.nih.gov/medlineplus/ency/article/001000.htm
National Institutes of Health Senior Health:
http://nihseniorhealth.gov/agerelatedmaculardegeneration/toc.html
National Eye Institute:
http://www.nei.nih.gov/health/maculardegen/armd_facts.asp
Prevent Blindness America:
http://www.preventblindness.org/eye_problems/amdFAQ.html
Foundation Fighting Blindness:
http://www.blindness.org/MacularDegeneration/
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